BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON New | — |
| LISA NELSON New | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Trade (domestic/foreign) TRD
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Taxation/Internal Revenue Code TAX
Proposed policies regarding corporate tax reform regarding all bio-pharmaceutical related provisions. No bill number Import Taxes regarding all bio-pharmaceutical related provisions. No bill number.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DEOUDES | — |
| LANE PENRY | — |
| PAUL ANTHONY WILLIAMS | — |
Copyright/Patent/Trademark CPT
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1435/H.R. 2873 - Affordable Prescriptions for Patients Act of 2021 - prohibition on product hopping
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Medicare/Medicaid MMM
H.R. 2163 - To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health regarding all bio-pharmaceutical related provisions H.R. 19 - Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes regarding all bio-pharmaceutical related provisions H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON New | — |
| LISA NELSON New | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.